NICE Recommends BeiGene's BRUKINSA (zanubrutinib) for Patients with Waldenström's Macroglobulinemia who have had at Least One Treatment Seite 1

20.09.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and ... Seite 1

Related Keywords

Ireland ,United Kingdom ,Robert Mulrooney ,University College London Hospitals Centre ,National Health Service ,Beigene General Manager ,Beigene ,